Alzamend Neuro, Inc. (ALZN) intrinsic value & 10-year financials
Alzamend Neuro, Inc. (ALZN) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.30
- Market cap
- $4.3M
- Revenue (FY2026)
- —
- ROIC (10-yr avg)
- -186.4%
- Free cash flow (FY2026)
- —
ALZN 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2026 | — | -$8.8M | -$2.63 | — | — | -373.2% |
| FY2025 | — | -$4.5M | -$11.32 | — | — | 169.1% |
| FY2024 | — | -$9.9M | -$14.70 | — | — | 372.6% |
| FY2023 | — | -$14.9M | -$0.15 | — | — | -181.5% |
| FY2022 | — | -$12.4M | -$0.14 | — | — | -160.9% |
| FY2021 | — | -$5.0M | — | — | — | -356.1% |
| FY2020 | — | -$4.4M | — | — | — | -774.7% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Alzamend Neuro, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Alzamend Neuro, Inc. has historically struggled to out-earn its cost of capital, averaging just 2.7% ROIC.
Alzamend Neuro, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Alzamend Neuro, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.